[go: up one dir, main page]

CL2013003792A1 - Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante. - Google Patents

Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante.

Info

Publication number
CL2013003792A1
CL2013003792A1 CL2013003792A CL2013003792A CL2013003792A1 CL 2013003792 A1 CL2013003792 A1 CL 2013003792A1 CL 2013003792 A CL2013003792 A CL 2013003792A CL 2013003792 A CL2013003792 A CL 2013003792A CL 2013003792 A1 CL2013003792 A1 CL 2013003792A1
Authority
CL
Chile
Prior art keywords
mammals
express
recombinant protein
cell culture
stop
Prior art date
Application number
CL2013003792A
Other languages
English (en)
Inventor
Brian D Follstad
Rebecca E Mccoy
Arvia E Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2013003792A1 publication Critical patent/CL2013003792A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2013003792A 2011-07-01 2013-12-30 Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante. CL2013003792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503737P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
CL2013003792A1 true CL2013003792A1 (es) 2014-07-25

Family

ID=46579326

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013003792A CL2013003792A1 (es) 2011-07-01 2013-12-30 Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante.
CL2016001190A CL2016001190A1 (es) 2011-07-01 2016-05-18 Cultivo de células de mamífero.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016001190A CL2016001190A1 (es) 2011-07-01 2016-05-18 Cultivo de células de mamífero.

Country Status (23)

Country Link
US (7) US11292829B2 (es)
EP (2) EP2837680B1 (es)
JP (1) JP5897708B2 (es)
KR (8) KR20230114317A (es)
CN (2) CN107988166B (es)
AU (5) AU2012279230C1 (es)
BR (2) BR112013033730B1 (es)
CA (2) CA2952347A1 (es)
CL (2) CL2013003792A1 (es)
CY (2) CY1118863T1 (es)
DK (2) DK2837680T3 (es)
EA (1) EA039023B1 (es)
ES (2) ES2625045T3 (es)
HU (2) HUE033279T2 (es)
IL (6) IL315908A (es)
LT (2) LT2837680T (es)
MX (2) MX387489B (es)
PL (2) PL2726600T3 (es)
PT (2) PT2726600T (es)
SG (1) SG10201702537RA (es)
SI (2) SI2837680T1 (es)
WO (1) WO2013006479A2 (es)
ZA (1) ZA201309372B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
KR20110091678A (ko) 2008-10-20 2011-08-12 아보트 러보러터리즈 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
HUE033279T2 (en) * 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
BR112014009031A2 (pt) 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
MX2015000337A (es) 2012-07-09 2015-09-25 Coherus Biosciences Inc Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
LT2895188T (lt) 2012-09-11 2018-04-10 Coherus Biosciences, Inc. Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas
WO2014109858A1 (en) * 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
SG11201507875RA (en) * 2013-03-26 2015-10-29 Coherus Biosciences Inc Protein production method
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
HUE071397T2 (hu) * 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
SG10201806643WA (en) 2014-01-13 2018-09-27 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
ES2909630T3 (es) * 2014-06-04 2022-05-09 Amgen Inc Métodos de recolección en cultivos de células de mamífero
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
JP6530171B2 (ja) * 2014-09-09 2019-06-12 旭化成メディカル株式会社 培養産生物の回収方法
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105385731B (zh) * 2015-12-25 2018-10-30 上海莱士血液制品股份有限公司 一种表达重组八因子的灌注培养方法
EP3400242A1 (en) * 2016-01-06 2018-11-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2017149065A1 (en) 2016-03-02 2017-09-08 Lonza Ltd Improved fermentation process
SG11201908891YA (en) * 2017-03-31 2019-10-30 Boehringer Ingelheim Int Perfusion medium
EP3601586A1 (en) 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
WO2018229802A1 (en) * 2017-06-16 2018-12-20 Ge Healthcare Bio-Sciences Ab Method for predicting outcome of and modelling of a process in a bioreactor
CA3070579A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
JP7323512B2 (ja) 2017-10-06 2023-08-08 ロンザ リミテッド ラマン分光法を使用する細胞培養の自動制御
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
SG11202005272SA (en) * 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CA3104684A1 (en) * 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
SG11202106609WA (en) * 2018-12-31 2021-07-29 Repligen Corp Filter for mammalian cell culture perfusion and clarification with hydrophobic hollow fiber
WO2021058713A1 (en) * 2019-09-27 2021-04-01 Boehringer Ingelheim International Gmbh Concentrated perfusion medium
CN116391043A (zh) * 2020-08-14 2023-07-04 百时美施贵宝公司 蛋白质的制造方法
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
CN114574430A (zh) * 2022-03-22 2022-06-03 成都博宠生物科技有限公司 一种Expi293F细胞培养方法
CN115287251A (zh) * 2022-08-25 2022-11-04 无锡药明生物技术股份有限公司 间歇性灌流联合分批流加培养
AU2023338683A1 (en) 2022-09-06 2025-03-13 Amgen Inc. Lean perfusion cell culture methods
AU2023340945A1 (en) 2022-09-16 2025-03-13 Amgen Inc. A method for harvesting products from perfusion cultures
WO2024220354A1 (en) * 2023-04-15 2024-10-24 Puerto Rico Science Technology & Research Trust Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof
WO2025029614A1 (en) 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
CN116790483B (zh) * 2023-08-22 2023-10-20 苏州依科赛生物科技股份有限公司 一种cho细胞无血清培养基及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4499064A (en) 1982-06-03 1985-02-12 Clayton Foundation For Research Assessment of nutritional status of individuals
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US7037721B1 (en) * 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
KR101004174B1 (ko) 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
US20030036505A1 (en) 2000-09-25 2003-02-20 Human Genome Sciences, Inc. Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
CA2447791A1 (en) 2001-06-13 2002-12-19 Neslihan Delacruz Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003083066A2 (en) 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
CN104593277A (zh) * 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
CN1332024C (zh) * 2004-06-09 2007-08-15 中国科学院大连化学物理研究所 一种海绵细胞的微载体三维培养方法
EP2156852B1 (en) 2004-07-07 2011-04-13 Coloplast A/S Catheter comprising ESTANE 58212.
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
JP2008518597A (ja) * 2004-10-29 2008-06-05 セントカー・インコーポレーテツド 化学的規定培地組成物
PL2267024T3 (pl) * 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT2634243T (pt) 2006-07-14 2017-12-18 Patheon Holdings I B V Método para melhorar a cultura de células
US20080206819A1 (en) * 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
KR101523782B1 (ko) 2006-11-08 2015-05-28 와이어쓰 엘엘씨 세포 배양을 위한 합리적으로 설계된 배지
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP3327132A3 (en) 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
HRP20180738T1 (hr) 2008-09-15 2018-06-15 F. Hoffmann - La Roche Ag Pripravci i postupci za regulaciju stanične osmolarnosti
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
BR112012002151B1 (pt) 2009-07-31 2021-07-06 Baxalta GmbH método para expressar uma desintegrina e metaloproteinase com proteína de motivo trombospondina (adamts)
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
NO2501822T3 (es) 2009-11-17 2018-01-13
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
ES2692379T3 (es) * 2010-11-01 2018-12-03 Symphogen A/S Anticuerpos anti-HER3 y composiciones
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
HUE033279T2 (en) * 2011-07-01 2017-11-28 Amgen Inc Mammalian cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
HUE071397T2 (hu) 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
HK1259103A1 (zh) * 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法

Also Published As

Publication number Publication date
EA039023B1 (ru) 2021-11-23
KR20180050433A (ko) 2018-05-14
US20230129523A1 (en) 2023-04-27
US20230227535A1 (en) 2023-07-20
AU2018203972A1 (en) 2018-06-21
AU2018203972B2 (en) 2020-09-17
DK2726600T3 (en) 2017-05-15
KR101662412B1 (ko) 2016-10-04
AU2020281075C1 (en) 2025-06-26
AU2018203972C1 (en) 2025-06-26
EP2726600A2 (en) 2014-05-07
US20220185869A1 (en) 2022-06-16
KR20220021008A (ko) 2022-02-21
AU2012279230A1 (en) 2014-01-09
PT2726600T (pt) 2017-04-24
CA2838695C (en) 2017-02-14
BR122021007265B1 (pt) 2022-02-22
IL288509B (en) 2022-12-01
KR20200051046A (ko) 2020-05-12
LT2837680T (lt) 2020-07-10
SG10201702537RA (en) 2017-04-27
BR112013033730B1 (pt) 2022-01-25
WO2013006479A3 (en) 2013-03-28
SI2837680T1 (sl) 2020-07-31
HK1206057A1 (en) 2015-12-31
KR102761360B1 (ko) 2025-02-05
CL2016001190A1 (es) 2017-06-09
PL2837680T3 (pl) 2020-08-10
AU2012279230B2 (en) 2016-08-18
MX387489B (es) 2025-03-18
ES2625045T3 (es) 2017-07-18
IL315908A (en) 2024-11-01
AU2016244255A1 (en) 2016-10-27
KR102358951B1 (ko) 2022-02-08
US11685772B2 (en) 2023-06-27
CN107988166A (zh) 2018-05-04
JP2014520534A (ja) 2014-08-25
PT2837680T (pt) 2020-04-17
US11827692B2 (en) 2023-11-28
IL310968A (en) 2024-04-01
EP2726600B1 (en) 2017-02-15
HUE033279T2 (en) 2017-11-28
EP2837680A1 (en) 2015-02-18
HUE049119T2 (hu) 2020-09-28
IL297998A (en) 2023-01-01
KR102558247B1 (ko) 2023-07-24
US11292829B2 (en) 2022-04-05
IL310968B1 (en) 2024-11-01
ES2788132T3 (es) 2020-10-20
CA2838695A1 (en) 2013-01-10
KR20140031375A (ko) 2014-03-12
SI2726600T1 (sl) 2017-07-31
CA2952347A1 (en) 2013-01-10
AU2023201127B2 (en) 2025-10-16
WO2013006479A2 (en) 2013-01-10
KR20240005106A (ko) 2024-01-11
KR102108663B1 (ko) 2020-05-07
BR112013033730A2 (pt) 2017-01-31
DK2837680T3 (da) 2020-04-27
IL297998B1 (en) 2024-03-01
AU2020281075B2 (en) 2022-12-22
EA201391826A1 (ru) 2014-04-30
US20200407427A1 (en) 2020-12-31
IL288509B2 (en) 2023-04-01
CY1123146T1 (el) 2021-12-31
KR20250021605A (ko) 2025-02-13
JP5897708B2 (ja) 2016-03-30
CN103827292B (zh) 2018-01-26
KR20160075814A (ko) 2016-06-29
MX351974B (es) 2017-11-06
US20140255993A1 (en) 2014-09-11
KR101857380B1 (ko) 2018-05-11
IL310968B2 (en) 2025-03-01
IL229803B (en) 2020-11-30
AU2023201127A1 (en) 2023-03-30
IL278430B (en) 2022-01-01
LT2726600T (lt) 2017-05-25
IL288509A (en) 2022-01-01
HK1197081A1 (en) 2015-01-02
CN107988166B (zh) 2022-03-15
US20210061888A1 (en) 2021-03-04
PL2726600T3 (pl) 2017-08-31
CY1118863T1 (el) 2018-01-10
US11634476B2 (en) 2023-04-25
AU2020281075A1 (en) 2021-01-07
KR20230114317A (ko) 2023-08-01
US11673941B2 (en) 2023-06-13
MX2013014937A (es) 2014-04-16
US20230117598A1 (en) 2023-04-20
AU2012279230C1 (en) 2025-06-19
EP2837680B1 (en) 2020-02-26
ZA201309372B (en) 2014-08-27
IL297998B2 (en) 2024-07-01
CN103827292A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
CL2013003792A1 (es) Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante.
EP2681306A4 (en) CELL CULTURE SYSTEM
BR112013033711A2 (pt) processo para fermentar singás e para iniciar fermentador principal para fermentação de singás
EP2667915A4 (en) INJEKTOR
PL2719190T3 (pl) Dostarczanie treści segmentowanej przestrzennie
CL2014003568A1 (es) Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante.
DK2675502T4 (da) Automatisk injektor
IL240644B (en) Cell culture compositions with antioxidants and methods for polypeptide production
BR112014013034A2 (pt) método para produzir um anticorpo
HRP20181152T1 (hr) Progenitorne stanice mezodermalnog porijekla
DK2775557T3 (da) Brændselscelle
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
EP2692421A4 (en) COMPOSITE MEMBRANE
CL2015001787A1 (es) Yogures con un alto contenido de proteinas y metodo para producirlos.
CO7240426A2 (es) Célula hospedera bacteriana recombinante para expresión de proteína
CO6870003A2 (es) Vacunas bovinas y métodos
EP2743172A4 (en) TANK SUPPORT STRUCTURE AND FLOATING CONSTRUCTION
BR112013029769A2 (pt) levedura recombinante
BR112014002624A2 (pt) microorganismo recombinante e cultura de microorganismo recombinante
FI20116314L (fi) Koostumus sulautettuun mikrobiviljelyyn
EP3066193C0 (en) CELL CULTURE PROCESS
FI20116212L (fi) Polypeptidi
CL2014001181A1 (es) Kit para el cultivo mejorado de células in vitro que comprende sustitucion de suero y factores labiles
EP2734541A4 (en) NEW IL-17R ECD MUTANTS
EP2794841A4 (en) BIOREACTOR